

CURRICULUM VITAE

Name: Alva Bowen Weir, III, M.D., F.A.C.P.

Current Appointments: The West Clinic
100 N. Humphrys Blvd.
Memphis, TN 38120
901-683-0055
www.westclinic.com

2005 to Present Veterans Administration Hospital
1030 Jefferson Avenue
Medicine Service
Memphis, TN 38104

Previous Appointments:

2007-2011 University of Tennessee Cancer Institute
1331 Union Avenue, Suite 800
Memphis, TN 38104

1992-9/1/05 TheWest Clinic, 100 N. Humphreys,
Memphis, TN 38120

9/1/89-9/1/05 Private Practice, Hematology and Oncology,
Memphis, Tennessee

10/1/82-7/30/85 Consultant, Internal Medicine, Eku Baptist Hospital,
Eku, Nigeria

1979-83 Private Practice, Internal Medicine, Baptist Memorial Hospital,
Memphis, Tennessee

1991- Fellow, Americal College of Physicians-American
Society of Internal Medicine (ACP-ASIM)
Philadelphia, PA

1996-2004	National board member Christian Medical and Dental Associations
1999-2001	President Elect, Christian Medical & Dental Society (National)
2001-2003	President, Christian Medical and Dental Associations
2003-	Board member Albanian Health Fund
9/1/05-1/1/10	Vice President of Campus and Community Ministries, Christian Medical and Dental Associations.
9/1/08—present	Attending Physician, Veteran's Affairs Medical Center, Clinical Professor of Medicine, UTCHS Associate Program Director Hematology/Oncology Fellowship
1/1/09---present	NCCN Panel Member on Chemotherapy Induced Anemia
3/1/10---present	NCCN Panel on Senior Adult Oncology

Education:

Undergraduate:

Southwestern at Memphis (now Rhodes College) B.A., 69-1971

Graduate / Medical School:

University of Tennessee College of Medicine
Memphis, TN
M.D. 7/6/72 - 6/8/75

Internship:

Intern in Internal Medicine
Barnes Hospital
St. Louis, MO 7/1/1975-6/30/1976

Residency:

Resident in Internal Medicine
City of Memphis Hospitals
Memphis, Tennessee 7/1/1976-6/30/1978

Postgraduate:

Fellow in Hematology / Oncology
University of Alabama
Birmingham, AL 7/1/1978-6/30/1979
and
University of Tennessee College of Medicine
Memphis, Tennessee 6/16/85 - 6/15/86

Military Service:

None

Certification:

American Board of Internal Medicine 1978

Medical Oncology 1987

Hematology 1988

Societies:

Honorary: Phi Beta Kappa, Alpha Omega Alpha
 Fellow American College of Physicians 1989
 American Society of Clinical Oncology
 American Society of Hematology

University Appointments:

7/1/79-6/30/81	Clinical Instructor, Internal Medicine, University of Tennessee College of Medicine, Memphis, Tennessee
7/1/81-6/30/83	Clinical Assistant Professor, Internal Medicine, University of Tennessee, Memphis, Tennessee
7/1/86-8/30/89	Assistant Professor, Internal Medicine, Division Hematology and Oncology, University of Tennessee, Memphis,
9/1/89-6/30/92	Clinical Assistant Professor, Internal Medicine, University of Tennessee, Memphis, Tennessee
7/1/92-6/30/99	Clinical Associate Professor, Internal Medicine, University of Tennessee, Memphis, Tennessee
7/1/99-9/1/05	Clinical Professor, Internal Medicine, University of Tennessee, Memphis, Tennessee
7/1/2008- 10/1/08 Johnson City, TN	Clinical Professor, Internal Medicine, East Tennessee State
2/01/09--- present	Clinical Professor, Internal Medicine, U Tenn, Memphis
7/01/10---present UTHSC	Assistant Program Director, Hematology Oncology fellowship

Research Interests:

1. Co-Principle Investigator NCCN funded trial:

A Phase I/II Trial of the Combination of Cisplatin, Cetuximab, and Temsirolimus
 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

2. Co-Principle Investigator at VA site for Systematic Review of the Product of Surgical Resection in the Memphis Metropolitan Area (MMA): OSI-TAR-763. Funded to \$55,750. On-going project.
3. Principle Investigator: Chronic Idiopathic Neutrophilia in Veterans; an ongoing project accepted as poster presentation at the 1st World Congress on Controversies in Hematology
4. Principle Investigator: Severe Neutropenia in Hepatitis C Positive Veterans Not Undergoing Anti-Viral Therapy in the Veteran's Administration Hospital in Memphis, Tennessee
5. Principle Investigator: Evaluation of a Tool for Physicians to Improve the Informed Consent Process in the Hematology/Oncology Clinic at Veteran's Administration Hospital, Memphis Tennessee.
6. Principle Investigator: Evaluation of Decision-making of Cancer Patient and Non-cancer Hospice Patient Death in Intensive care Unit at the veterans Affairs Medical center, Memphis, TN.

Teaching Awards

1. Faculty of the Year Veteran's Affairs Medical Center Department of Medicine 2009-2010
2. Faculty of the Year University of Tennessee Division of Hematology 2009-2010

BOOKS

1. Contributing author, Chapter 9-Oncology, *Handbook of Medicine in Developing Countries*, 2nd ed., (Bristol, TN: Paul Tournier Institute, 2002)
2. Weir, A.B., *When Your Doctor Has Bad News*, (Grand Rapids, MI: Zondervan, 2003)
3. Weir, MD, Al & Rudd, MD, Gene, *Practice by the Book - A Christian Doctor's Guide To Living and Serving*, (Bristol, TN: Christian Medical Association, 2005)

JOURNAL PUBLICATIONS

1. Brown, R. and Weir, A.B.: Drug fever from Tolmetin administration. JAMA 239-24, 1978
2. Weir, A.B., Poon, M., McGowan, E.: Plasma exchange for idiopathic

- thrombocytopenic purpura. *Lancet*.1978. Sep 23;2 (8091): 689.
3. Weir, A.B., Poon, M., McGowan, E.: Plasma exchange for idiopathic thrombocytopenic purpura. *Arch. Int. Med.* 140:1101-03, 1980.
 4. Weir, A.B., Poon, M., Groarke, J., Wilkerson, J.: Lymphoma simulating Crohn's Colitis. *Digestive Diseases and Sciences* 25(1):69-72, 1980.
 5. Weir, A.B., Agbowu, J., Ajayi, N.: Hyperendemic West African trypanosomiasis in a rural hospital setting. *Journal of Tropical Medicine and Hygiene.* 1985. Oct;88 (5): 307-11.
 6. Neely, C., Weir, A.B.: Therapy of metastatic breast cancer. *American Cancer Society Professional Education Newsletter.* 16(1):1, 1987.
 7. Weir, III, A. B., Woods, L. L., Chesney, C., Neitzer, G.: Delayed hemolytic transfusion reaction caused by anti-LebH antibody. *Vox Sang.* 1987; 53(2) : 105-07.
 8. Weir, A.B., Dow, L.: Response of agranulocytosis to thymectomy in a patient with thymoma and chronic lymphocytic leukemia. *Med. Ped. Oncol.* 17:58-11, 1989.
 9. Weir, A.B., Herrod, H.D., Lester, E., Holbert, J.: Diffuse large-cell lymphoma of B-cell origin and deficient T-cell function in a patient with rheumatoid arthritis. *Arch. Int. Med.* 149:1688-90, 1989.
 10. Weir, A.B., Niell, H.B., Griffin, J.P.: 5-fluorouracil infusion and mitomycin combination chemotherapy in the management of patients with advanced non-small cell lung cancer. *Am. Jour. Clin. Oncol.* 12(6):521-3, 1989.
 11. Sullivan, J. and Weir, A.B.: The management of hypertension in the patient with cerebrovascular disease. *Practical Cardiology* Feb. 93
 12. Fontanesi, J., Clark, C., Weir, A.B., et al: Concomitant Cisplatin and I¹²⁵ Interstitial Implantation followed by hyperfractionated external beam irradiation (HEBI) for primary supratentorial malignant gliomas. *Am. Jour. Clin. Onc.* 16(5):412-417, 1993.
 13. Robbins, K. T., Fontanesi, J., Wong, F.S., Vicario, D., Seagren, S., Kumar, P., Weisman, R., Pellitteri, P., Thomas, J.R., Flick, P., Palmer, R., Weir, III, A., Kerker, C., Murry, T., Ferguson, R., Los, G., Orloff, L., Howell, S.B.: A novel organ preservation protocol for advanced carcinoma of the larynx and pharynx. *Arch Otolaryngol Head Neck Surg;* 122(8):853-7 1996.
 14. K.Thomas Robbins, M.D., Parvesh Kumar,M.D., William F. Regine, Frank S. H. Wong,

- M. D., Alva B. Weir, III, M. D., et al: Efficacy of Targeted Supradose Cisplatin and Concomitant Radiation Therapy for Advanced Head and Neck Cancer: The Memphis Experience. *Int. J. Radiation Oncology Biol. Phys.*, Vol. 38, No. 2, pp. 263-271, 1997.
15. Robbins, K.T., Kumar, P., Wong, F.S., Hartsell, W.F., Flick, P., Palmer, R., Weir, III, A. B., Neill, H.B., Murry, T., Ferguson, R., Hanchett, C., Vieira, F., Bush, A., Howell, S.B.: Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients, *Head and Neck*; 22(7): 687-93 2000.
 16. Schwartzberg LS, Petak I, Stewart C, Turner PK, Ashley J, Tillman DM, Douglas L, Tan M, Billups C, Mihalik R, Weir A, Tauer K, Shope S, Houghton, JA. Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin. *Clin Cancer Res.* 2002 Aug;8(8): 2488-98.
 17. Weir AB, Where Faith and Medicine Meet. *Community Oncology.* 2006 June; 3 (6): 372-376.
 18. Weir AB, The Four Percent Solution. *Health and Development.* 2007 Volume 27 (1) 11-14.
 19. Rodgers GM, et al. Cancer and chemotherapy induced anemia. *NCCN Guidelines Version 2.2011.*
 20. Hurria A, et al. Senior oncology. *NCCN Guidelines Version 2.2011.*
 21. Hurria A, et al. Senior oncology. *NCCN Guidelines Version 2.2012*
 22. Weir A, Lewis J, Arteta-Bullos R. Chronic idiopathic neutrophilia: experience and recommendations. *Southern Medical Journal.* 2011; 104(7): 499-504.
 23. Weir A, Brint JM. Hope is a verb: a course correction in delivering bad news. *Am J Hospice Palliat Care.* Epub ahead of print. April 2011.

Completed manuscripts submitted to peer reviewed journals

24. Ganti A, DeShazo M, Weir A, Hurria A. Treatment of non-small cell lung cancer in the older patient. *J Nat Comp Cancer Center.* Requested manuscript.
25. Weir A, Ganti A, Samant S, DeShazo M, Hurriss A. Management of squamous cell cancer of the head and neck in the elderly. *J Geriatric Oncol.* Requested manuscript;
26. Sheehan V, Weir A, Waters B. Severe neutropenia in hepatitis B patients not receiving antiviral therapy. Submitted for publication.

ABSTRACTS

1. Hunter, R.F., Griffin, J.P., Neill, H.B., Weir, A.B. and Bronze, M.S.: Alternating noncross resistant chemotherapy in small cell lung cancer. Proc. Am. Soc. Clin. Onc. 5:172, 1986.
2. Lester, E., Babin, R., Weir, A.B., Kavanagh, K., Beckford, N.: Sequential methotrexate, cisplatin, 5-fluorouracil infusion, and leucovorin in advanced head and neck cancer. Proc. Am. Soc. Clin. Onc. 5:143, 1986.
3. Weir, A.B., Neill, H.B., Griffin, J.P., Hunter, R.F. and Lands, R.: 5-fluorouracil and mitomycin C based combination chemotherapy in the treatment of patients with Stage III non-small cell lung cancer. Proc. Am. Soc. Clin. Onc. 6:171, 1987.
4. Weir, A.B., Neill, H.B., Neely, C.A., Lester, E.P., Hunter, R.F., Lands, R.: Sequential methotrexate, 5-FU infusion, high dose Leucovorin, and mitomycin therapy in patients with advanced colon cancer. Proc. Am. Soc. Clin. Onc. 6:91, 1987.
5. Lester, E., Weir, A.B., Beckford, N., Budoff, A., et al: Sequential methotrexate, cisplatin, 5-fluorouracil infusion, and Leucovorin in previously untreated Stage III and IV head and neck cancer. Proc. Am. Soc. Clin. Onc. 6:128, 1987.
6. Robbins, K.T., Kumar, P., Weisman, R. A., Wong, F.S., Hartsell, W., Weir, III, A.B., Neill, B., Los, G., Christen, R., Palmer, R., Seagren, S. L., Ferguson, R., Flick, P. A., Kerber, C.W., Howell, S. B., Phase II trial of targeted supradose Cisplatin (DDP) and concomitant radiation therapy (RT) for patients with stage III-IV head and neck cancer (Meeting abstract)., Proc Annu Meet Am Soc Clin Oncol; 15:A920 1996.
7. K. T. Robbins, F.S.H. Wong, B. Mullins, A. Weir, III, L. Newman, C. Oster, R. Palmer, P. Flick, S. Williams, R. Ferguson, H. B. Neill, P. Kumar. The University of Tennessee, Memphis, Phase II Pilot Trial of Reduced Dose Radiation Therapy and Concomitant Targeted Cisplatin Chemotherapy (NEORADPLAT) for head and Neck cancer., Head Neck 1998 Vol 20, 474.
8. L. Schwartzberg, J. Houghton, D. Phillips, J. Geller, L. Douglas, A. Weir, K. Tauer, K. Turner, C. Stewart; The West Clinic, Memphis, TN; St. Jude Children's Research Hospital, Memphis, TN, Phase I Study of Interferon Gamma (INF- γ) added to

Bolus/Infusional 5-Fluorouracil (5-FU) and Leucovorin (LV) for Advanced Colorectal Carcinoma (CRC)., ASCO GI Cancer Symposium, Jan 27-29, 2005.

9. Weir A, Rajanna K, Naini P. Evaluation of patient comprehension of risk/benefit/goals of chemotherapy in a VA Oncology Clinic. Proceedings 6th Annual Meeting of Association of Vetrean Affairs Hematology Oncology Organization. 2010.
10. Arteta-Bulos R, Weir A, Lewis J. Chronic idiopathic neutrophilia: retrospective analysis of causes and consequences. Blood (ASH Annual Meeting Abstracts) 2010;116: Abstract 4717.
11. ASCO Abstract #79135
A phase I/II trial of the combination of cisplatin, cetuximab, and temsirolimus in recurrent or metastatic squamous cell carcinoma of the head and neck.
J. W. Allen, F. Yunus, S. Samant, H. B. Niell, T. McKibbin, M. Sebelik, A. B. Weir III; University of Tennessee Cancer Institute, Memphis, TN; University of Tennessee Health Science Center, Memphis, TN; Veterans Affairs Hospital, Memphis, TN
12. ASCO Abstract #82119
Evaluation of a methodology for physicians to improve the consent process of chemotherapy.
P. Naini, A. B. Weir III, K. Rajanna, J. Lewis; University of Tennessee Cancer Institute, Memphis, TN; VA Medical Center, Memphis, TN
13. L. E. Miller, R. A. Ramirez, C. Wang, T. O'Brien, A. B. Weir III, H. Cole, R. U. Osarogiagbon. Number and location of examined lymph nodes (LN) and survival after resection of 'node-negative' non-small cell lung cancer (NSCLC). Accepted as publication only for American Society of Clinical Oncology Annual Meeting 2011.
14. C. Wang, L. E. Miller, R. A. Ramirez, M. T. Chi, M. Ul-Haq, R. A. Arteta-Bulos, A. Farooq, J. W. Allen, A. B. Weir III, H. Cole, T. O'Brien, R. U. Osarogiagbon. Comparison of survival between the American joint committee on cancer (AJCC) 6 and 7 lung cancer staging systems in a resection cohort. Accepted as publication only for American Society of Clinical Oncology Annual Meeting 2011.
15. R. U. Osarogiagbon, R. A. Ramirez, C. Wang, L. E. Miller, M. Ul-Haq, A. Farooq, J. W. Allen, D. Spencer, A. Berry, A. B. Weir III, H. Cole, T. O'Brien. Survival analysis of patients with/without lymph node examination after lung cancer resection. Accepted for poster presentation at American Society of Clinical Oncology Annual Meeting 2011.
16. C. Wang, R.A. Ramirez, L.E. Miller, A. Farooq, J.W. Allen, A.B. Weir, A. Berry, T. O'Brien, F.H. Cole, R.U. Osarogiagbon. The state of pathology examinations after resection of lung

cancer: a trend analysis before and after quality improvement interventions and summary of ongoing problems. Accepted for poster presentation at 14th World Conference on Lung Cancer.